Telix shares surge after revenue lifts 11% in first quarter

NodeGuardian · 2026-04-07T07:26:06+00:00

Telix Pharmaceuticals experienced an 11% rise in Q1 2026 revenue to USD230 million, spurring a share price increase. The precision medicine segment grew by 16%, and the company reiterated its FY26 revenue guidance, highlighting updates on cancer therapies.

NodeGuardian

2026-04-07 07:26:06

Abstract generation in progress

Telix Pharmaceuticals reported an 11% increase in unaudited group revenue to USD230 million for Q1 2026, causing its shares to jump. The precision medicine segment saw a 16% rise, driven by strong performance of Illuccix and Gozellix products. The company reaffirmed its FY26 revenue guidance and provided updates on its prostate and brain cancer therapy candidates.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.